1987 Volume 28 Issue 4 Pages 583-588
A case of chronic myelomonocytic leukemia (CMMoL) which was successfully treated with low dose Ara-C is reported.
A 64-years-old male was admitted with subcutaneous bleeding on March 31, 1982. Although the WBC count and percentage of monocytes in peripheral blood were high, 20,600/cmm and 32% respectively, RBC and PLT counts were normal. A bone marrow aspirate revealed a hypercellular material (NCC 32×104/cmm) with granulocytic and monocytic hyperplasia. The lysozyme was increased in serum and urine, and the patient was diagnosed as CMMoL.
Thereafter, he was treated only with some hemostatic drugs as an outpatient for approximately 2 years. On July 2, 1984, he was re-admitted with massive subcutaneous bleeding and marked hepatosplenomegaly. After the re-admission, skin eruptions were also increased and diagnosed as leukemia cutis by a biopsy. Leukemia cutis was disappeared and hepatosplenomegaly was remarkably decreased in size after subcutaneous injections of low dose Ara-C (14mg×2/day) for 14 days.
While the standard protbcol for CMMoL treatment has not been decided yet, the low dose Ara-C therapy was recommended as an useful treatment to CMMoL from our experimental study.
